• Acrux has 4 marketed products in the US and 6 ANDA products approved to date
• Targeting topical drugs with $21B US market, 40 products >$100M sales each
• Leveraging expertise in topical drug development and commercial partnerships

Acrux is a specialty pharmaceutical company with a 25+ year track record of developing and commercializing topically applied prescription products in the US and globally. The company has 4 marketed products in the US, 6 ANDA products approved to date, and a pipeline targeting the $21 billion US topical pharmaceuticals market. Acrux has unique capabilities for topical drug development, including in-house R&D, a TGA-approved GMP facility, and a network of contract manufacturers. The company identifies high-potential topical drug candidates, develops them through regulatory approval, and commercializes them through licensing deals. Acrux has generated $20 million in total revenue over FY23 and FY24, with additional new product launches planned. The company's long-term growth model is focused on expanding its diversified, revenue-generating portfolio of topical products through continued pipeline investment and strategic commercial partnerships.

Acrux expects to generate additional revenue from the recent approval of Efinaconazole Topical Solution and the planned launches of Dapsone 7.5% Gel and Nitroglycerin Rectal Ointment in FY25.

Acrux is well-positioned for continued growth, with a strong pipeline of 8 topical products under development and plans to add 2 new pipeline projects per year as existing products are approved and launched. The company's focus on the $21 billion US topical pharmaceuticals market, unique development capabilities, and strategic commercial partnerships provide a solid foundation for long-term success.